Sonia Lopez
Addiction Medicine · Jamaica, NYNPI 1134281975
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,600 of the $14,024 with a category attached, or 68.5%. Gilead accounts for 64.8% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $8,883, more than ten times the $330 reported in 2019. Among addiction medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $79.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- Alkermes, Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Indivior Inc.$163
- AbbVie$163
- Johnson & Johnson$160
- plus $703 from 14 others
What the payments were for
- Consulting fees$9,60068%
- Speaking & faculty fees$130%
- Food & beverage$4,37531%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 28 | $9,083 |
| Alkermes, Inc. | 38 | $2,349 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 68 | $1,403 |
| Indivior Inc. | 7 | $163 |
| AbbVie | 2 | $163 |
| Johnson & Johnson | 5 | $160 |
| Braeburn Inc. | 2 | $147 |
| Orexo US, Inc. | 7 | $129 |
| Neurocrine Biosciences, Inc. | 4 | $96 |
| Viiv Healthcare Company | 2 | $47 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| IBSA Pharma Inc. | 2 | $39 |
| Pfizer | 1 | $34 |
| Lundbeck LLC | 1 | $29 |
| Merck | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| USWM, LLC | 1 | $16 |
| Napo Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,024 in reported general payments places this provider in the 90th percentile of 125 addiction medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $10,661 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $8,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $163 | $8,91014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 125 addiction medicine providers in New York.
Other addiction medicine in Jamaica
- Edmond HakimiCalverton$125K
- Alain LitwinBronx$124K
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Alejo ParelladaBrooklyn$22K
- Sean ChappinAlbany$20K
- Mohammad KabirTroy$15K
- Thomas KuettelWorcester$14K
- Ramon RaveloNew York$13K
- Stuart GitlowNew York$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.